INTERROGATING SOS1/2 (SON OF SEVENLESS 1 AND 2) AS THERAPEUTIC TARGETS IN TREATMENT-RESISTANT EGFR AND K-RAS-DRIVEN LUNG CANCER
$372,212FY2017Department of the ArmyDOD
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.